Caffeine citrate injection

Phase 3

HeartSciences Inc. (HSCSW)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Apnea of Prematurity

View Full Landscape

Drug Information

Target Indication

Apnea of Prematurity

Clinical Trial

NCT01020357

Last updated: 8/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Blectifor

Indicated in preterm neonates for the prevention of bronchopulmonary dysplasia

Orphan

View on EMA

EMA8/19/2020

Gencebok

Treatment of primary apnoea of premature newborns.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

HSCSW

HeartSciences Inc.

Finance Services•North America•NASDAQ

Related Pipeline

Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]Phase 3

Iron-deficiency

Sacubitril-Valsartan 49 Mg-51 Mg Oral TabletPhase 3

Obesity

Mono-Therapy with SildenafilPhase 3

Pediatric Pulmonary Hypertension

Convalescent PlasmaPhase 3

Covid19

FosinoprilPhase 3

Microalbuminuria

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts